Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer

Objectives: Accumulating evidence has illustrated greater benefit of immunotherapy in tumors with high tumor mutation burden (TMB), whereas its impact on targeted therapy or chemotherapy is undefined. Herein, we evaluated TMB outside of immuno-oncology in epidermal growth factor receptor (EGFR)–muta...

Full description

Bibliographic Details
Main Authors: Chen Lin, Xun Shi, Jun Zhao, Qiong He, Yun Fan, Weizhen Xu, Yang Shao, Xinmin Yu, Ying Jin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
tumor mutation burden (TMB)
clinical benefit
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
chemotherapy
non–small cell lung cancer (NSCLC)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00480/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00480/full

Similar Items